TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TAI · 1789.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
ScinoPharm Taiwan, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
ScinoPharm Taiwan, Ltd.’s forward annual dividend is NT$0.29 per share, paid annual. The forward yield is 1.45% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
ScinoPharm Taiwan, Ltd.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of NT$0.16. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ScinoPharm Taiwan, Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ScinoPharm Taiwan, Ltd., along with its subsidiaries, specializes in the research, development, production, and global distribution of cGMP-compliant active pharmaceutical ingredients (APIs). The company supplies these APIs to pharmaceutical clients throughout Taiwan, the United States, Europe, India, various parts of Asia, and other international regions. Its service offerings include custom synthesis for biochemical molecules like peptides and nucleic acids, manufacturing of generic APIs, and comprehensive outsourcing solutions. ScinoPharm also provides Contract Research and Manufacturing (CRAM) services, which involve chemistry expertise, analytical and regulatory support, chemical process development, clinical drug substance manufacturing, and consulting. These CRAM services facilitate the creation and production of APIs and intermediates for clinical, small-scale, and commercial applications. Moreover, the company actively develops advanced peptide synthesis technologies. ScinoPharm is involved in the development and manufacturing of a diverse range of products, such as Western medicines, various chemical materials, albumin-based drugs, oligonucleotide medicines, injectables, and novel small molecule drugs, alongside offering biotechnology and technical services. The company holds a strategic alliance with Baxter International Inc. focused on the joint development, production, and commercialization of an antiemetic drug for cancer chemotherapy. ScinoPharm Taiwan, Ltd. was founded in 1997 and has its headquarters in Tainan City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$650.00M0.0% vs estimate |
| Q4 2024 | Feb 26, 2025 | NT$0.030.0% vs estimate | NT$662.00M0.0% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | NT$0.04-50.0% vs estimate | NT$724.00M-2.16% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$56.70-NT$0.20 (-0.35%)
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
NT$51.00-NT$0.60 (-1.16%)
SCI Pharmtech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.98% below the high.
NT$45.95-NT$0.55 (-1.18%)
Formosa Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.82% below the high.
NT$32.30-NT$1.10 (-3.29%)
Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.82% below the high.
NT$27.15-NT$1.35 (-4.74%)
Prince Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.67% below the high.
